On February 5 Boston Scientific announced results for the fourth quarter and full year 2019. For implantable devices, the relevant numbers are:
Q4:
- Cardiac Rhythm Management $473M in Q4 2019 vs $488M in Q4 2018, or a reported drop of 3.3%
- Neuromodulation $261M in n Q4 2019 vs $220M in Q4 2018, or a reported increase of 18.7%
FY 2019:
- Cardiac Rhythm Management $1,939M in 2019 vs $1,951M in 2018, or a reported drop of 0.6%
- Neuromodulation $873M in 2019 vs $779M in 2018, or a reported increase of 12.0%